EA201691202A1 - FLAGELLIN-CONTAINING PROTEIN NANOPARTICLES AS A PLATFORM FOR VACCINE - Google Patents

FLAGELLIN-CONTAINING PROTEIN NANOPARTICLES AS A PLATFORM FOR VACCINE

Info

Publication number
EA201691202A1
EA201691202A1 EA201691202A EA201691202A EA201691202A1 EA 201691202 A1 EA201691202 A1 EA 201691202A1 EA 201691202 A EA201691202 A EA 201691202A EA 201691202 A EA201691202 A EA 201691202A EA 201691202 A1 EA201691202 A1 EA 201691202A1
Authority
EA
Eurasian Patent Office
Prior art keywords
flagellin
vaccine
platform
containing protein
protein nanoparticles
Prior art date
Application number
EA201691202A
Other languages
Russian (ru)
Other versions
EA037258B8 (en
EA037258B1 (en
Inventor
Питер БУРКХАРД
Сентил Кумар Раман
Сара Мария Паулильо
Маттео Пьяцца
Кэролайн КУЛАНГАРА
Кристиан Миттельхольцер
Original Assignee
Альфа-О Пептидс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Альфа-О Пептидс Аг filed Critical Альфа-О Пептидс Аг
Priority claimed from PCT/EP2015/050289 external-priority patent/WO2015104352A1/en
Publication of EA201691202A1 publication Critical patent/EA201691202A1/en
Publication of EA037258B1 publication Critical patent/EA037258B1/en
Publication of EA037258B8 publication Critical patent/EA037258B8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к белковым наночастицам, обладающим способностью самосборки, сконструированным из подходящих доменов олигомеризации и дополнительно включающих TLR5-связывающий белок флагеллин в качестве молекулы адъюванта. Более того, настоящее изобретение относится к применению таких наночастиц для вакцинации.The present invention relates to protein nanoparticles having the ability to self-assembly, constructed from suitable oligomerization domains and further comprising the TLR5 binding protein flagellin as an adjuvant molecule. Moreover, the present invention relates to the use of such nanoparticles for vaccination.

EA201691202A 2014-10-16 2015-01-09 Flagellin-containing protein nanoparticles for immunomodulation EA037258B8 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14189264 2014-10-16
PCT/EP2015/050289 WO2015104352A1 (en) 2014-01-09 2015-01-09 Flagellin-containing protein nanoparticles as a vaccine platform

Publications (3)

Publication Number Publication Date
EA201691202A1 true EA201691202A1 (en) 2017-01-30
EA037258B1 EA037258B1 (en) 2021-02-26
EA037258B8 EA037258B8 (en) 2022-02-22

Family

ID=51798969

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691202A EA037258B8 (en) 2014-10-16 2015-01-09 Flagellin-containing protein nanoparticles for immunomodulation

Country Status (1)

Country Link
EA (1) EA037258B8 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013144579A1 (en) * 2012-03-30 2013-10-03 Heriot-Watt University Use of flagellin as a vaccine

Also Published As

Publication number Publication date
EA037258B8 (en) 2022-02-22
EA037258B1 (en) 2021-02-26

Similar Documents

Publication Publication Date Title
EA201790294A1 (en) FLAGELLIN BASED MEANS AND APPLICATIONS INCLUDING EFFECTIVE VACCINATION
CY1125084T1 (en) NUCLEIC ACID VACCINES
TR201908550T4 (en) Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications.
EA201891083A1 (en) COMPOSITIONS OF ANTIBODIES TO CD38 FOR SCRAPTURE AND THEIR APPLICATION
MX2021001098A (en) Single domain antibodies directed against intracellular antigens.
EA201791485A1 (en) ANTI-CD47-ANTIBODIES AND THEIR APPLICATIONS
EA201692512A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT BY SYNTHETIC NANOSEMS AND INHIBITORS OF THE IMMUNE CONTROL POINT
EA201692301A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
BR112017023374A2 (en) anti-cgrp antibody formulation
BR112016027893A2 (en) trypecific binding molecule and pharmaceutical composition
EA201790248A1 (en) MEDIA-ANTIBODY COMPOSITIONS AND METHODS FOR THEIR RECEIVING AND APPLICATION
EA201692177A1 (en) CONNECTIONS AND COMPOSITIONS AS AN AGONISTS OF TOLL-LIKE RECEPTOR 7
EA201790239A1 (en) MOLECULE CARRIER FOR ANTIGENS
EA201691582A1 (en) NEW PHARMACEUTICAL PREPARATIONS
EA201691988A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
EA201591451A1 (en) FLAP MODULATORS
EA201790507A1 (en) METHODS AND COMPOSITIONS FOR STRENGTHENING IMMUNE RESPONSES
EA201790773A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING BIOLOGICAL ACTIVITY OF SOLUBLE BIOMOLECULES
EA201791249A1 (en) CD44V6-RECEIVED CYCLIC PEPTIDES FOR THE TREATMENT OF MALIGNANT TUMORS AND ANGOGENESIS-ASSOCIATED DISEASES
MX2022002635A (en) Angiopoietin-like 4 antibodies and methods of use.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX363149B (en) Influenza nucleoprotein vaccines.
EA202091567A1 (en) CHIMERIC PROTEINS MIT